Atlas Trials

A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Clinical trial NCT05353205 · UNKNOWN

Trial details

NCT number
NCT05353205
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
CML, Chronic Phase
Start date
2021-11-23
Primary completion
2022-12-30
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.